Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Solid Tumors
Hepatic Impairment

Interventions: Drug: Dovitinib

First Posted Date: 2011-09-29

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT01443481

Locations: 🇺🇸
University of California at Los Angeles Dept. of UCLA (4), Los Angeles, California, United States
🇺🇸
Duke University Medical Center DUMC, Durham, North Carolina, United States
🇺🇸
Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, United States

and more 1 locations

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Phase 1

Completed

Conditions: Mild Moderate
or Severe Renal Impairment

Interventions: Drug: AFQ056

First Posted Date: 2011-09-28

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01442259

Locations: 🇩🇪
Novartis Investigative Site, Kiel, Germany

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod
Drug: other disease-modifying therapy

First Posted Date: 2011-09-28

Last Posted Date: 2022-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3076

Registration Number: NCT01442194

Locations: 🇵🇷
Novartis Investigative Site, San Juan, Puerto Rico

Sickle Cell Disease: A Retrospective Chart Review

Completed

Conditions: Sickle Cell Anemia

First Posted Date: 2011-09-27

Last Posted Date: 2012-10-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 261

Registration Number: NCT01441375

Locations: 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
Universit of Tennessee, Memphis, Tennessee, United States

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Thrombocytopaenia

Interventions: Drug: eltrombopag
Drug: placebo

First Posted Date: 2011-09-26

Last Posted Date: 2017-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT01440374

Locations: 🇹🇭
Novartis Investigative Site, Songkla, Thailand

Dose Finding Study for QAW039 in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: QAW039
Drug: Montelukast
Drug: Placebo

First Posted Date: 2011-09-21

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1043

Registration Number: NCT01437735

Locations: 🇬🇧
Novartis Investigative Site, Glasgow - Scotland, United Kingdom

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Phase 4

Terminated

Conditions: Depression
Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Fluoxetine
Drug: Venlafaxine
Drug: Citalopram
Drug: Fingolimod

First Posted Date: 2011-09-20

Last Posted Date: 2014-09-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT01436643

Locations: 🇩🇪
Novartis Investigative Site, Zwickau, Germany

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

Phase 1

Completed

Conditions: Insulin Resistance

Interventions: Drug: BVS857
Drug: Placebo

First Posted Date: 2011-09-16

Last Posted Date: 2015-04-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT01435330

Locations: 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: RLX030A

First Posted Date: 2011-09-14

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT01433458

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Phase 1

Completed

Conditions: Post Polycythemia-Vera Myelofibrosis
Idiopathic Myelofibrosis
Post Essential Thrombocythemia Myelofibrosis

Interventions: Drug: panobinostat
Drug: ruxolitinib

First Posted Date: 2011-09-14

Last Posted Date: 2021-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT01433445

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy